1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Aspergillosis Global Clinical Trials Review, H2, 2014

Aspergillosis Global Clinical Trials Review, H2, 2014

  • November 2014
  • -
  • Global Data
  • -
  • 124 pages

Aspergillosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Aspergillosis Global Clinical Trials Review, H2, 2014" provides data on the Aspergillosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aspergillosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Aspergillosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Aspergillosis Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Aspergillosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Aspergillosis to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Aspergillosis to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Aspergillosis 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Aspergillosis Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Aspergillosis 33
Sep 02, 2014: F2G announces commencement of a Phase 1 single ascending dose study of a novel antifungal agent, F901318 33
Clinical Trial Profiles 34
Clinical Trial Overview of Top Companies 34
Astellas Pharma Inc. 34
Clinical Trial Overview of Astellas Pharma Inc. 34
Pfizer Inc. 36
Clinical Trial Overview of Pfizer Inc. 36
Merck and Co., Inc. 37
Clinical Trial Overview of Merck and Co., Inc. 37
Gilead Sciences, Inc. 38
Clinical Trial Overview of Gilead Sciences, Inc. 38
Scynexis, Inc. 39
Clinical Trial Overview of Scynexis, Inc. 39
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
Janssen Pharmaceuticals, Inc. 41
Clinical Trial Overview of Janssen Pharmaceuticals, Inc. 41
iCo Therapeutics Inc. 42
Clinical Trial Overview of iCo Therapeutics Inc. 42
F2G Ltd 43
Clinical Trial Overview of F2G Ltd 43
Eli Lilly and Company 44
Clinical Trial Overview of Eli Lilly and Company 44
Clinical Trial Overview of Top Institutes / Government 45
National Cancer Institute 45
Clinical Trial Overview of National Cancer Institute 45
Postgraduate Institute of Medical Education and Research 46
Clinical Trial Overview of Postgraduate Institute of Medical Education and Research 46
Asan Medical Center 47
Clinical Trial Overview of Asan Medical Center 47
Seoul National University Hospital 48
Clinical Trial Overview of Seoul National University Hospital 48
University of Cologne 49
Clinical Trial Overview of University of Cologne 49
University of Pittsburgh 50
Clinical Trial Overview of University of Pittsburgh 50
University of Arkansas 51
Clinical Trial Overview of University of Arkansas 51
Nagasaki University 52
Clinical Trial Overview of Nagasaki University 52
The National Institute of Allergy and Infectious Diseases 53
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 53
PETHEMA 54
Clinical Trial Overview of PETHEMA 54
Five Key Clinical Profiles 55
Appendix 122
Abbreviations 122
Definitions 122
Research Methodology 123
Secondary Research 123
About GlobalData 124
Contact Us 124
Disclaimer 124
Source 124

List of Tables
Aspergillosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Aspergillosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aspergillosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aspergillosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Aspergillosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Aspergillosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Aspergillosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Aspergillosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Aspergillosis to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Aspergillosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aspergillosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aspergillosis to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Aspergillosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Aspergillosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Aspergillosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Aspergillosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Aspergillosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Aspergillosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Aspergillosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Aspergillosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Aspergillosis Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Aspergillosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Aspergillosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Aspergillosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Aspergillosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Aspergillosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 34
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 36
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 37
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 38
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Scynexis, Inc., 2014* 39
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Pharmaceuticals, Inc., 2014* 41
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by iCo Therapeutics Inc., 2014* 42
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by F2G Ltd, 2014* 43
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 44
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 45
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014* 46
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 47
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 48
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Cologne, 2014* 49
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 50
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Arkansas, 2014* 51
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nagasaki University, 2014* 52
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 53
Aspergillosis Therapeutics Clinical Trials Market, Global, Clinical Trials by PETHEMA, 2014* 54

List of Figures

Aspergillosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Aspergillosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aspergillosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aspergillosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Aspergillosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Aspergillosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Aspergillosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Aspergillosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Aspergillosis to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Aspergillosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aspergillosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aspergillosis to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Aspergillosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Aspergillosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Aspergillosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Aspergillosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Aspergillosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Aspergillosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Aspergillosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Aspergillosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Aspergillosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Aspergillosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Aspergillosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 123

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.